MétaCan
Menu
Back to cohort

Real world outcomes in extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation (cTRT) and chemoimmunotherapy (CIT): A population level study.

2024· article· en· W4399670554 on OpenAlexaff
Amanda Williams Gibson, Michelle L. Dean, Marc Kerba, Vishal Navani

Bibliographic record

VenueJournal of Clinical Oncology · 2024
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Research Studies
Canadian institutionsAlberta Health ServicesUniversity of Calgary
Fundersnot available
KeywordsChemoimmunotherapyMedicineLung cancerStage (stratigraphy)OncologyRadiation therapyPopulationInternal medicineRadiologyChemotherapySurgeryCyclophosphamide

Abstract

fetched live from OpenAlex

e20111 Background: Despite recent survival improvements from the combination of immune checkpoint inhibitors (ICI) with chemotherapy for patients with ES-SCLC, outcomes remain limited for the majority of patients. Addition of cTRT may elicit a synergistic response and contribute to improved disease control and survival, but there is limited data supporting routine use from either the trial or real world contexts. This study aims to investigate the safety and time-to-event outcomes of patients treated with CIT and cTRT. Methods: Demographic, clinical, treatment and outcome details were extracted from the Glans-Look Lung Cancer Research Database, a province-wide real-world outcomes registry of patients treated in routine practice. A population-level cohort of ES-SCLC patients receiving CIT and cTRT between 2019 and 2023 were identified. Results: 30 patients were identified. Median age was 68y. At CIT initiation; 63% had ECOG performance status ≤ 1, 17% had brain metastases; 20% received prophylactic cranial irradiation. CIT was comprised of platinum-etoposide and ICI: durvalumab (67%) or atezolizumab (33%), followed by maintenance ICI (median 5.8 months). cTRT was administered a median 4.8 months after CIT initiation; n=13 (43%) received 30Gy/10, n=2 (7%) received dose escalation to 40-45Gy in 14-20 fractions, and n= 15 (50%) received 20Gy-25Gy over 5-10 fractions. Reasons for discontinuation of CIT were primarily to progressive disease (n=18, 75%); with n=16 patients receiving second line systemic treatment (94% chemotherapy, 6% durvalumab rechallenge), and n=1 receiving additional thoracic stereotactic ablative body radiation. Post-cTRT pneumonitis was recorded in n=3 (10%) of patients, ranging from (CTCAE v5.0 Grade 1-3 severity), requiring hospitalization + treatment break (n=1), ICI termination (n=1), or resolving without intervention (n=1). Time-to-event outcomes are presented in the table. Receiving durvalumab as opposed to atezolizumab did not impact either mPFS (10 vs. 12 months, log rank=0.4; HR: 1.3 [95% CI: 0.8 - 5.9], p=0.12) or OS (17 vs. 13.2 months, log rank p=0.87; HR: 2.2 [95% CI: 0.4 – 4.4], p=0.67). Conclusions: ES-SCLC treatment comprised of both CIT and cTRT appears feasible and effective in among real-world patients. Pneumonitis, a potential complication of combined ICI and thoracic radiation, was infrequently observed in this cohort. Use of cTRT in addition to CIT appears to numerically surpass the ~13-month mOS observed within clinical trials which used first-line CIT without additional cTRT for ES-SCLC. [Table: see text]

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.045
Threshold uncertainty score0.488

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.165
GPT teacher head0.544
Teacher spread0.379 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicLung Cancer Research StudiesFrench-language works237,207